Stock Market Reviews

INBS (Intelligent Bio Solutions Inc.) News

Get the latest news, insights, and market updates on INBS (Intelligent Bio Solutions Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Intelligent Bio Solutions Successfully Manufactures and Ships First Readers with New Partner, Accelerating Scale and Driving Gross Margin Expansion in Anticipation of Planned U.S. Entry
  Successful delivery in partnership with Syrma Johari validates manufacturing scale, strengthens commercial readiness, and supports planned U.S. market entry in 2026 Partnership on track to deliver annual production cost savings of more than 40% with expected improvement of approximately 20 percentage points in gross margin annually Doubled in-house lateral flow test strip production capacity strengthens vertical integration, accelerates R&D, and enables panel expansion NEW YORK, Feb. 25, 2026 (G
  Feb 25, 2026 - $INBS
• Intelligent Bio Solutions Partners with Bouygues UK, Part of Multi-Billion Dollar Global Construction Giant Bouygues Construction, for UK Drug Testing Rollout
  Initial 13-site deployment with UK subsidiary of global construction firm employing 35,600 employees across 50+ countries, validates commercial scalability and ROI of INBS’s fingerprint drug testing technologyNEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced a partnership with Bouygues UK, a subsidiary of Bouygues Construct
  Feb 24, 2026 - $INBS
• Intelligent Bio Solutions Reports Record Fiscal Second Quarter Revenue Growth of 48% with Reader Sales Surging 104% Year-Over-Year
  First half fiscal 2026 revenue surpasses $2 million, up 36% year-over-year Reader sales more than double to 104% year-over-year for the second quarter, demonstrating razor-razorblade model momentum Gross profit margins for first half fiscal 2026 increased 10% year-over-year to 49%, reflecting improved operational efficiency Current assets balance of $12.17 million as of December 31, 2025, including $9.40 million receivable in connection with the private placement of securities that closed on Jan
  Feb 12, 2026 - $INBS
• Intelligent Bio Solutions Expects to Report Fiscal Second Quarter 2026 Revenue Growth of Approximately 48% Year-Over-Year, Surpassing $2 Million in Total Revenue for First Half of Fiscal Year
  Expected record fiscal second quarter revenue increase driven by expanding customer base and strong growth across all product categories Reader sales expected to post year-over-year growth of more than 100% in fiscal Q2, expanding installed base to drive sustained recurring cartridge revenue NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions
  Feb 5, 2026 - $INBS
• Intelligent Bio Solutions Initiates Additional Clinical Studies for FDA 510(k) Submission Supporting Planned Entry into Multi-Billion Dollar U.S. Market
  Clinical studies designed to support FDA clearance and planned commercial launch into the world’s largest drug screening market Company anticipates full data analysis by the end of March 2026; data to be incorporated into FDA 510(k) submission package NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the commencement of its
  Jan 28, 2026 - $INBS
• Top Midday Decliners
  Intelligent Bio Solutions (INBS) reported late Wednesday an agreement with two healthcare-focused in
  Jan 2, 2026 - $INBS
• Intelligent Bio Solutions Announces Closing of $10.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
  NEW YORK, Jan. 02, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (“INBS” or the “Company”) (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the closing of its previously announced private placement with two healthcare focused institutional investors priced at-the-market under Nasdaq rules of 2,298,850 shares of common stock (or pre-funded warrants in lieu thereof), Series K-1 warrants to purchase up to an aggreg
  Jan 2, 2026 - $INBS
• Intelligent Bio Solutions Announces New Manufacturing Partnership to Strengthen Global Production Capability and Increase Margins
  Partnership with Syrma Johari Medtech, a globally recognized medical device engineering and manufacturing organization, expands INBS’ global manufacturing capacity, strengthens supply-chain resilience, and supports an expected improvement of approximately 20 percentage points in gross margin ahead of planned U.S. market entryNEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rap
  Dec 31, 2025 - $INBS
• Intelligent Bio Solutions Announces $10.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
  NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (“INBS” or the “Company”) (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that it entered into a securities purchase agreement with two healthcare focused institutional investors to issue, in a private placement priced at-the-market under Nasdaq rules, 2,298,850 shares of common stock (or pre-funded warrants in lieu thereof), Series K-1 warrants t
  Dec 31, 2025 - $INBS
• BC-Most Active Stocks
  td class="col-issue">New Era Energy & Digital Inc.
  Dec 31, 2025 - $INBS